Study group | Number of patients | |
---|---|---|
Epithelial ovarian cancer patients | 110 (100%) | |
• Median age (range) | 58 (46–80) | |
-sub-type serous epithelial | 61 (55%) | |
• Median age (range) | 58 (46–81) | |
-sub-type endometrioid epithelial | 49 (45%) | |
• Median age (range) | 59 (48–86) | |
Tumor stage | IA | 6 (5.4%) |
IB | 8 (7.3%) | |
IC | 14 (12.7%) | |
IIA | 9 (8.2%) | |
IIB | 10 (9.1%) | |
IIC | 9 (8.2%) | |
IIIA | 10 (9.1%) | |
IIIB | 10 (9.1%) | |
IIIC | 8 (7.3%) | |
IV (metastases) | 26 (23.6%) | |
Menopausal status: - postmenopausal | 110 (100%) | |
Benign ovarian tumor patients | 70 (100%) | |
-type cystis serous | 35 (50%) | |
-type cystis endometrioides | 35 (50%) | |
Median age (range) | 52 (48–68) | |
Menopausal status: - postmenopausal | 70 (100%) | |
Healthy subjects | 50 (100%) | |
Median age (range) | 56 (48–66) | |
Menopausal status: - postmenopausal | 50 (100%) |